DISP-11 / Dispatch Biotherapeutics - LARVOL DELTA

CARsgen Therapeutics Holdings Limited and Dispatch Bio have announced a clinical collaboration to test a novel combination therapy for solid tumors, with a Phase 1 trial slated to begin in China in 2026. (Indian Pharma Post) - "The study will evaluate DISP-11, an investigational therapy combining Dispatch Bio’s first-in-class Flare platform—including the novel tumor-specific virus DV-10—with CARsgen’s zevorcabtagene autoleucel....The trial will focus on patients with epithelial-origin solid tumors, which make up 90% of all solid tumors. Participants will first receive DV-10, followed by administration of zevor-cel."

Commercial • New P1 trial • Solid Tumor